TY - JOUR T1 - Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 2983 LP - 2990 VL - 35 IS - 5 AU - SHINSUKE KAZAMA AU - JOJI KITAYAMA AU - MASAYA HIYOSHI AU - YOSHITAKA TAKETOMI AU - MAKOTO MURAKAMI AU - TAKESHI NISHIKAWA AU - TOSHIAKI TANAKA AU - JUNICHIRO TANAKA AU - TOMOMICHI KIYOMATSU AU - KAZUSHIGE KAWAI AU - KEISUKE HATA AU - HIRONORI YAMAGUCHI AU - HIROAKI NOZAWA AU - SOICHIRO ISHIHARA AU - EIJI SUNAMI AU - TOSHIAKI WATANABE Y1 - 2015/05/01 UR - http://ar.iiarjournals.org/content/35/5/2983.abstract N2 - Background: Although secretory phospholipase A2 (sPLA2) has been shown to be involved in various biological processes, its specific roles in sub-types of cancer development remain to be elucidated. Materials and Methods: We examined the expression of sPLA2 group III (GIII) in 142 patients with colorectal cancer using immunohistochemistry, and its correlation with clinicopathological features and outcomes. In addition, we examined the co-expression of sPLA2GIII and sPLA2GX using serial tissue sections to clarify the roles of both proteins in colorectal carcinogenesis. Results: In 66 cases, diffuse staining of sPLA2GIII was seen; this was defined as the group with high expression. High expression was associated with a significantly higher rate of lymph node metastasis (p=0.02) and poorer survival (p=0.03) compared with low expression. Patients with low sPLA2GIII and high sPLA2GX expression had a significantly higher survival rate than those with high sPLA2GIII and low sPLA2GX expression (p=0.038). Conclusion: sPLA2GIII expression may be used as a risk factor for lymph node metastasis and a prognostic marker in colorectal cancer. In addition, sPLA2GIII and sPLA2GX may play opposing roles in colorectal carcinogenesis. ER -